JPWO2023059846A5 - - Google Patents

Info

Publication number
JPWO2023059846A5
JPWO2023059846A5 JP2024520869A JP2024520869A JPWO2023059846A5 JP WO2023059846 A5 JPWO2023059846 A5 JP WO2023059846A5 JP 2024520869 A JP2024520869 A JP 2024520869A JP 2024520869 A JP2024520869 A JP 2024520869A JP WO2023059846 A5 JPWO2023059846 A5 JP WO2023059846A5
Authority
JP
Japan
Prior art keywords
composition
acid
anion
ionic liquid
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538700A (ja
JP2024538700A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/045977 external-priority patent/WO2023059846A1/en
Publication of JP2024538700A publication Critical patent/JP2024538700A/ja
Publication of JPWO2023059846A5 publication Critical patent/JPWO2023059846A5/ja
Publication of JP2024538700A5 publication Critical patent/JP2024538700A5/ja
Pending legal-status Critical Current

Links

JP2024520869A 2021-10-08 2022-10-07 薬物送達のためのイオン液体 Pending JP2024538700A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253623P 2021-10-08 2021-10-08
US63/253,623 2021-10-08
PCT/US2022/045977 WO2023059846A1 (en) 2021-10-08 2022-10-07 Ionic liquids for drug delivery

Publications (3)

Publication Number Publication Date
JP2024538700A JP2024538700A (ja) 2024-10-23
JPWO2023059846A5 true JPWO2023059846A5 (https=) 2025-10-10
JP2024538700A5 JP2024538700A5 (https=) 2025-10-10

Family

ID=84053300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520869A Pending JP2024538700A (ja) 2021-10-08 2022-10-07 薬物送達のためのイオン液体

Country Status (9)

Country Link
US (1) US20240408180A1 (https=)
EP (1) EP4412587A1 (https=)
JP (1) JP2024538700A (https=)
KR (1) KR20240082406A (https=)
CN (1) CN118382429A (https=)
AU (1) AU2022359915A1 (https=)
CA (1) CA3233824A1 (https=)
IL (1) IL311885A (https=)
WO (1) WO2023059846A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
GB202408689D0 (en) * 2024-06-17 2024-07-31 Rnassist Ltd Method of manufacturing a pharmaceutical composition

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2202520C (en) * 1994-10-13 2000-09-05 Masanobu Takeuchi Lyophilized pharmaceutical preparations capable of providing aqueous drug composition having property of reversible thermosetting gelation
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105683376A (zh) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
KR20160019553A (ko) 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
US10449254B2 (en) 2013-11-03 2019-10-22 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
WO2015168125A1 (en) 2014-04-28 2015-11-05 Recombinetics, Inc. Multiplex gene editing in swine
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
EP3686279B1 (en) 2014-08-17 2023-01-04 The Broad Institute, Inc. Genome editing using cas9 nickases
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016112242A1 (en) 2015-01-08 2016-07-14 President And Fellows Of Harvard College Split cas9 proteins
CN111918644A (zh) 2017-11-17 2020-11-10 哈佛大学校长及研究员协会 用于内部递送的离子液体
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
US20220257767A1 (en) 2019-04-03 2022-08-18 President And Fellows Of Harvard College Ionic liquids for drug delivery
WO2021102084A1 (en) 2019-11-22 2021-05-27 President And Fellows Of Harvard College Ionic liquids for drug delivery
WO2022254209A1 (en) * 2021-06-04 2022-12-08 Imperial College Innovations Limited Stable composition

Similar Documents

Publication Publication Date Title
JP3626755B2 (ja) インターロイキン−1インヒビターの薬学的処方物
CN101559229B (zh) 在肺内区域作为活性物质载体的半氟化烷的吸入式和滴注式用途
JP3578455B2 (ja) 局所麻酔を回復させる方法およびそのための薬剤系
JP2022009013A (ja) 安定なニモジピン非経口製剤
JP4489356B2 (ja) 浸透促進剤
JP2021503468A5 (https=)
WO2000051629A1 (en) Preparations stabilized over long time
CN1203855C (zh) 左西孟旦的药物溶液
JP2013532729A5 (https=)
EP4516803A2 (en) Terlipressin compositions and their methods of use
IL318548A (en) Methods for treating muscular dystrophy with casimersen
CN1125635C (zh) 恩氟沙星注射液或输液
JP2019518798A (ja) リポヌクレオチドに基づくardsの治療
JPWO2023059846A5 (https=)
JP2002518468A5 (https=)
EP2277546B1 (en) Stable ready to use injectable paracetamol formulation
JPWO2020205409A5 (https=)
JP2011525531A5 (https=)
JPWO2021102084A5 (https=)
JP5674917B2 (ja) テトラチオモリブデン酸の治療的使用
JPWO2021168100A5 (https=)
JP2015524808A5 (https=)
JP5034944B2 (ja) インターフェロン作用物質の活性増強剤
JP2013500964A (ja) 静脈内イブプロフェンを用いた重篤な病気の患者の治療
US4039668A (en) Corticoid-containing inhalants